BusinessAxsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant DepressionBy Nasdaq OMXFeb 14, 2017, 12:02 PM UTC
BusinessAxsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant DepressionBy Nasdaq OMXFeb 14, 2017, 12:02 PM UTC
BusinessSummit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory MeetingsBy Nasdaq OMXFeb 1, 2017, 12:01 PM UTC
BusinessSummit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory MeetingsBy Nasdaq OMXFeb 1, 2017, 12:01 PM UTC
BusinessFDA Finally Addresses Synthetic Nicotine; Confirming Next Generation Labs’ Position that Synthetic Nicotine Is Not A Tobacco ProductBy Nasdaq OMXJan 20, 2017, 3:00 PM UTC
BusinessAdvanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera® NETTER-1 Phase III ResultsBy Nasdaq OMXJan 12, 2017, 1:05 PM UTC
BusinessAkari Therapeutics Expands Clinical and Regulatory Teams with Industry VeteransBy Nasdaq OMXJan 4, 2017, 12:00 PM UTC
Business1WorldSync Partners With FDA Consultant Globizz to Offer Unified Product Information Solution for Japanese Healthcare MarketplaceBy Nasdaq OMXDec 19, 2016, 11:00 PM UTC
